title: Impact of positron emission tomography with the use of fluorodeoxyglucose on response to induction chemotherapy in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma.
abstract: CONCLUSIONS
  Maximum standardized uptake values (SUVmax) have prognostic value for induction chemotherapy (ICT) response and survival in oropharyngeal and hypopharyngeal squamous cell carcinoma (OHSCC) patients. Pretreatment positron emission tomography with the use of fluorodeoxyglucose ((18)F-FDG PET) may be an aid in deciding the treatment strategy in OHSCC patients.
  
  
  OBJECTIVE
  We investigated the association between pretreatment (18)F-FDG PET and response to ICT and survival in OHSCC patients.
  
  
  METHODS
  We conducted a retrospective cohort study of 58 OHSCC patients treated at Aichi Cancer Center Hospital. The predictive impact of SUVmax of the primary tumor site was evaluated using statistical multivariate proportional hazard models.
  
  
  RESULTS
  Thirty-one cases (53%) were located in the oropharynx and 27 (47%) in the hypopharynx. Median SUVmax was 11.6 (range 3.2-23.5), and was significantly higher in the 8 patients with less than stable disease than in the 50 with more than partial response (median SUVmax, 17.3 vs 11.1; p = 0.002). In multivariate analysis, hazard ratios for the medium and high SUVmax groups relative to the low group were 3.07 (95% confidence interval, 0.62-15.29; p = 0.170) and 4.71 (0.97-22.89; p = 0.055), respectively, and the dose-response relationship was statistically significant (p trend = 0.047). A similar tendency was observed on subclassification by oropharynx and hypopharynx.
authors.affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kawakita
authors.forename: Takashi
authors.initials: T
authors.lastname: Masui
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Hanai
authors.forename: Taijiro
authors.initials: T
authors.lastname: Ozawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hirakawa
authors.forename: Akihiro
authors.initials: A
authors.lastname: Terada
authors.forename: Masami
authors.initials: M
authors.lastname: Nishio
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hosoi
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Hasegawa
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D018579:Patient Selection; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18